Compare EIC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | XOMA |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.8M | 322.7M |
| IPO Year | 2019 | N/A |
| Metric | EIC | XOMA |
|---|---|---|
| Price | $11.19 | $29.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $14.00 | ★ $63.25 |
| AVG Volume (30 Days) | 266.9K | ★ 371.9K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | 0.82 |
| Revenue | ★ $59,262,402.00 | $47,106,000.00 |
| Revenue This Year | $37.84 | $77.29 |
| Revenue Next Year | $23.33 | $34.91 |
| P/E Ratio | ★ $9.75 | $36.42 |
| Revenue Growth | 44.30 | ★ 118.02 |
| 52 Week Low | $10.81 | $18.35 |
| 52 Week High | $16.39 | $39.92 |
| Indicator | EIC | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 57.12 |
| Support Level | $10.93 | $25.30 |
| Resistance Level | $11.60 | $28.61 |
| Average True Range (ATR) | 0.23 | 1.58 |
| MACD | 0.00 | 0.66 |
| Stochastic Oscillator | 40.26 | 83.53 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.